US Pharma MarketingThe post MSD and Gilead scrap Phase III Trodelvy-Keytruda study on lacklustre interim data appeared first on Clinical Trials Arena.
MSD and Gilead scrap Phase III Trodelvy-Keytruda study on lacklustre interim data
This study miss marks a setback for Gilead’s Trodelvy expansion plans, which include both mono and combination therapy approaches. The post MSD and Gilead scrap Phase III Trodelvy-Keytruda study on lacklustre interim data appeared first on Clinical Trials Arena .
This study miss marks a setback for Gilead’s Trodelvy expansion plans, which include both mono and combination therapy approaches.
Source: Clinical Trials Arena